Why did West report a net loss in 2001 when income from continuing operations was positive?

The net loss of $5.2 million reflects a $25.2 million loss, or $1.76 per share, on the November 2001 sale of its contract manufacturing and packaging business. Income from continuing operations was $19.6 million, or $1.37 per share, and discontinued operations contributed a $0.4 million earnings amount, partly offset by that disposal loss.

How much of the company's sales come from outside the United States?

The filing states that direct sales to customers in the Asia/Pacific and South American markets were less than 11% of consolidated sales in 2001. The sales-by-country table shows U.S. sales of $222.9 million out of $396.9 million total, with Germany at $36.6 million and other European countries at $103.4 million.

How concentrated is the customer base?

Becton Dickinson and Company (BD) accounted for approximately 13% of 2001 consolidated net sales. The next ten largest customers, excluding BD, together accounted for approximately 30% of 2001 consolidated net sales, with no single one exceeding 4%.

What did the company say about its outlook for 2002?

Cash requirements for capital projects in 2002 are projected at approximately $40 million, focused on completing capacity expansion at two European plants, new product development, and continued rollout of an enterprise resource system. Management also expects pension income to continue to decrease in 2002 due to lower 2001 plan asset values, and it plans to use existing cash balances to pay down debt through an international financing structure.

WST 10-K FY2001 Annual Report — Revenue, Net Income, EPS

Q: What are the main debt terms and covenant risks?

Total debt was $193 million at year-end 2001, including $100 million of 6.81% senior notes due 2009 and a $114.5 million revolving credit agreement. The most restrictive covenant requires a minimum debt-to-total-capital ratio of 55%, and the company reported a ratio of 52.2% at December 31, 2001. Failure to meet covenants would make borrowings under the revolving facility immediately due.

01—Abstract

Summary

Summary of the 10-K filed March 28, 2002. Cited figures are marked; the original filing is the authoritative source.

West Pharmaceutical Services, Inc. reported 2001 net sales of $396.9 million^a, up from $378.6 million in 2000, with the filing noting that the strong U.S. dollar reduced reported sales by approximately $8 million and that sales at constant exchange rates were 7% higher.

Income from continuing operations was $19.6 million^b, or $1.37 per share, compared with $12.7 million, or $0.88 per share, in 2000. However, the company posted a net loss of $5.2 million, or $(0.36) per share, because of a $25.2 million loss on the November 2001 sale of its contract manufacturing and packaging business, which was treated as discontinued operations. Results also included a net restructuring charge of $2.9 million.

The Pharmaceutical Systems segment generated $376.4 million^c of net sales and operating profit of $69.2 million, while the Drug Delivery Systems segment's sales rose 31% to $20.5 million, driven mainly by licensing revenue tied to its chitosan-based nasal delivery technology (ChiSys). Gross margin was 29%, unchanged from 2000 but below 1999's 34%, with management citing production inefficiencies at several European plants. Selling, general and administrative expenses rose to $73.4 million, reflecting a $6 million decline in pension income.

Balance sheet and cash flow measures show cash of $42.1 million^d, debt of $193 million (down from $199.4 million), and a debt-to-total-invested-capital ratio of 52.2%. Operating cash flow fell to $31.1 million from $45.8 million, and capital spending was $44.1 million, with about $40 million projected for 2002. The company's most restrictive credit covenant requires a minimum debt-to-total-capital ratio of 55%, which investors should monitor given the current ratio.

02—Key points

Key Highlights

Net sales rose to $396.9 million in 2001 from $378.6 million in 2000; at constant exchange rates, sales were 7% higher.
Net loss of $5.2 million, or $(0.36) per share, driven by a $25.2 million ($1.76 per share) loss on the November 2001 sale of the contract manufacturing and packaging unit to DPT Lakewood, Inc. for $29.8 million.
Income from continuing operations increased to $19.6 million, or $1.37 per share, from $12.7 million, or $0.88 per share, in 2000.
Drug Delivery Systems revenue increased 31% to $20.5 million, mainly from licensing revenue tied to the ChiSys nasal delivery technology.
Gross margin held at 29% versus 34% in 1999, with production inefficiencies at several European plants cited as a factor.
Operating cash flow declined to $31.1 million from $45.8 million, and total debt was $193 million at year-end 2001, with a minimum debt-to-total-capital covenant of 55% against a reported ratio of 52.2%.
The company is the world's largest independent manufacturer of rubber stoppers for injectable drug vials, and it reports that it supplies a major portion of the U.S. market for pharmaceutical elastomer and metal packaging components.

03—Questions

Frequently Asked Questions

Why did West report a net loss in 2001 when income from continuing operations was positive?
The net loss of $5.2 million reflects a $25.2 million loss, or $1.76 per share, on the November 2001 sale of its contract manufacturing and packaging business. Income from continuing operations was $19.6 million, or $1.37 per share, and discontinued operations contributed a $0.4 million earnings amount, partly offset by that disposal loss.
How much of the company's sales come from outside the United States?
The filing states that direct sales to customers in the Asia/Pacific and South American markets were less than 11% of consolidated sales in 2001. The sales-by-country table shows U.S. sales of $222.9 million out of $396.9 million total, with Germany at $36.6 million and other European countries at $103.4 million.
How concentrated is the customer base?
Becton Dickinson and Company (BD) accounted for approximately 13% of 2001 consolidated net sales. The next ten largest customers, excluding BD, together accounted for approximately 30% of 2001 consolidated net sales, with no single one exceeding 4%.
What are the main debt terms and covenant risks?
Total debt was $193 million at year-end 2001, including $100 million of 6.81% senior notes due 2009 and a $114.5 million revolving credit agreement. The most restrictive covenant requires a minimum debt-to-total-capital ratio of 55%, and the company reported a ratio of 52.2% at December 31, 2001. Failure to meet covenants would make borrowings under the revolving facility immediately due.
What did the company say about its outlook for 2002?
Cash requirements for capital projects in 2002 are projected at approximately $40 million, focused on completing capacity expansion at two European plants, new product development, and continued rollout of an enterprise resource system. Management also expects pension income to continue to decrease in 2002 due to lower 2001 plan asset values, and it plans to use existing cash balances to pay down debt through an international financing structure.

04—Continue

← View all 10-K filings